Nursing Medical News about rheumatoid arthritis;infliximab vs etanercept

Become a Member Today!
Register

Most Viewed Abstracts

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Laas K et al. - Etanercept can be suggested in RA patients when infliximab has failed or discontinued for other reasons.

Methods

Disease activity was measured in RA pts (n=49) after switching from infliximab to etanercept
Reasons for infliximab discontinuation were: 42% for failure to respond by >ACR 50% criteria; 12% for AEs; 46% for non-medical reasons
Clinical outcome after the switch was compared between the groups according to the reason of infliximab discontinuation
Disease activity was measured with DAS28

Results

In pts in the non-medical reasons group, the disease activity was suppressed effectively both during infliximab and etanercept
One-year drug survival of etanercept in this group was the highest of 77% among the 3 groups
In pts in the infliximab failure and AE groups, DAS28 values improved during etanercept therapy
The 1-yr drug survival of etanercept was 43% and 50% respectively
For RA pts who discontinued taking infliximab because of non-medical reasons experienced similar treatment efficacy during both biological agents
The treatment with etanercept provided sufficient disease control also for pts with infliximab failure or AE

Denosumab update
Current Opinion in Rheumatology, 06/11/09

Sponsor